Replicel (TSE:RP) has released an update.
RepliCel Life Sciences Inc. has entered into a Letter of Intent for an asset purchase agreement with a company led by its CEO, aiming to sell all its patents and related assets in exchange for royalties on future sales. This strategic move, prompted by a challenging path to commercialization and funding, positions RepliCel to potentially avoid bankruptcy and offer future shareholder value as a delisted royalty company. The definitive agreement details are pending, with a planned delisting from TSX Venture Exchange and an asset commercialization timeline set between 2025 and 2027.
For further insights into TSE:RP stock, check out TipRanks’ Stock Analysis page.
